/Magdalene Sgagias/

Receipt date: '11/13/2007

EXAMINER SIGNATURE

PTO/SB/08A (08/03) (modified)

					U.S. Patent and Trade	nark Office; U	PTO/SB/08A (08/03) (modified S. DEPARTMENT OF COMMERCE	
Substitute for form 1449A/PTO				Application Number		TBA 10 580 24 X		
				International Filing Date First Named Inventor Art Unit		November 19, 2004 Mimi ADACHI, et al.		
		RMATION DISCLOS						
ST	ΑT	EMENT BY APPLICA	ANT					
		(use as many sheets as necessary)		Examine	r Name	Unassigned		
Sheet 1 of 4			Attorney Docket Number		64517.000003			
1 0I 4			Attorney Docket Number 64517.00					
		U.	S. PAT	ENT DO	CUMENTS			
*Examiner Initials	Cise No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY		Name of Paten Applicant of Cited		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
/M.S	/1.	US- 2005/0208659 A1	09-22-2005		Ikeda, et al.			
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
	L	US-						
	<u> </u>	US-		 				
	<u></u>	US-						
	_	US-						
		US-						
		US-						
	<u></u>	US-						
	L	US-						
	<u>_</u>	US-						
	_	US-						
		US-						
		US-			7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7			
	L.	US-						
	_	US-						
	1	US-						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

/Magdalene Sgagias/

DATE CONSIDERED

PTO/SB/08A (08/03) (modified)
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO Application Number TBA							- "				
Substitute for form 1449/110						International Filing Date		November 19, 2004			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT						First Named Inventor		Mimi ADACHI, et al.			
						Examiner Name		Unassigned			
Sheet		2 of	4			Atı	torney Docket Number	64517.000003			
	FOREIGN PATENT DOCUMENTS										
			REIGN PATENT DOCUMENT								
*Examiner	Cite	- 1	Country	y Code Number-Kind Publication I			Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION			
foldal	No.		Code (if known)		MM-DD-YYYY			<u> </u>	YES	NO	
/M.S	5,2.		wo	02/095026	11-28-200)2	Ikeda, et al.				
	_	_									
	_	_									
	Ĺ										
									□		
	L				L						
EXAMINER SIGNATURE /Magdalene Sgagias/			/	DATE CONSIDERED	03/18/2010						

^{*}EXAMMSER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08B (08/03) (modified)
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO			Application Number	TBA			
		TARREST OF THE	International Filing Date	November 19, 2004			
		MATION DISCLOSURE	First Named Inventor	Mimi ADACHI, et al.			
STA		MENT BY APPLICANT	Art Unit	TBA			
(use as many sheets as necessary)			Examiner Name	Unassigned			
Sheet 3 of 4			Attorney Docket Number	64517.000003			
OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS							
*Examinor	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the					
Iritials	No.		book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				
/M.S	3.	Tamamori-Adachi, et al., "Loss of skp2 Dependent Degradation of p27 Limits Cardiomyocyte Proliferative Capacity Induced by Cyclin DINLS/CDK4," 26th Annual Meeting of the Molecular Biology Society of Japan Program Abstract, November 25, 2003, pg.438, 01-6.					
	4.	Tamamori-Adachi, et al., "Critical Role of Cyclin D1 Nuclear Import in Cardiomyocyte Proliferation," Circulation Research, Vol. 92, No. 1, pg. 1-8, 2003.					
	5.	Poolman, et al., "Altered Expression of Cell Cycle Proteins and Prolonged Duration of Cardiac Myocyte Hyperplasia in p27 ⁽⁸⁸⁾ Knockout Mice," Circulation Research, Vol. 85, No. 2, pg. 117-127, 1999.					
	6.	Kim. et al., "Successful Inactivation of Endogenous Oct-314 and c-mos genes in Mouse Preimpiantation Embryos and Oocyees using Shorn Interfering RNAs," Biochemical and Biophysical Research Communications, Vol. 296, pp. 1372-1377, 2002.					
	7.	Toyoshima, et al., "p27, a Novel Inhibitor of GI Cyclin-Cdk Protein Kinase Activity, Is Related to p21," Cell, Vol. 78, No.1, pg. 67-74, July 15, 1994.					
	8.	Tsvetkov, et al., "p21 ^{Kip1} Ubiquitination and Degradation is Regulated by the SCP ^{Sip2} Complex Through Phosphorylated Thr187 in p27," Current Biology, Vol. 9, No.12, pg. 661-664, 1999.					
	9.	Pasumarthi, et al., "Cardiomyocyte Cell Cycle Regulation," Circulation Research, Vol. 90, pg. 1044-1054, 2002.					
	10.	Kirshenbaum, et al., "Adenovirus EIA Represses Cardiac Gene Transcription and Reactivates DNA Synthesis in Ventricular Myocytes, Via Alternative Pocket Protein- and p300-binding Domains," The Journal of Biological Chemistry, Vol. 270, No. 14, pg. 7791-7794, 1995.					
	11.	Kirshenbaum, et al., "Human E2F-1 Reactivates Cell Cycle Progression in Ventricular Myocytes and Represses Cardiac Gene Transcription," Developmental Biology, Vol. 179, pg. 402-411, 1996.					
	12.	Soonpaa, et al., "Cyclin DI Overexpression Promotes Cardiomyocyte DNA Synthesis and Multinucleation in Transgenic Mice," J. Clin. Invest., Vol. 99, No. 11, pg. 2644-2654, June 1997.					
	13.	Toyoda, et al., "jumonji Downregulates Cardiac Cell Proliferation by Repressing cyclin DI Expression," Developmental Cell, Vol. 5, pg. 85-97, July 2003.					
EXAMINER SIGNATURE //Magdalene Sgagias/ DATE CONSIDERED 03/18/2010							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

PTO/SB/08B (08/03) (modified) U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE								
Substitute for	form 1449/PTO	Application Number	TBA					
		International Filing Date	November 19, 2004					
	RMATION DISCLOSURE	First Named Inventor	Mimi ADACHI, et al.					
	EMENT BY APPLICANT	Art Unit	ТВА					
	(use as many sheets as necessary)	Examiner Name	Unassigned					
Sheet	4 of 4	Attorney Docket Number	64517.000003					
	OTHER DOCUMENTS - NON-	PATENT LITERATURE	DOCUMENTS					
Examiner Chr	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the							
Iriuals No.	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				NO			
/M.S./	Increased Cyclin-dependent Kinase Inl	Flink, et al., "Changes in E2F Complexes Containing Retinoblastoma Protein Family Members and Increased Cyclin-dependent Kinase Inhibitor Activities During Terminal Differentiation of Cardiomycoytes," J. Mol. Cell. Cardiol., Vol. 30, pg. 563-578, 1998.						
15.	von Harsdorf, et al. "E2F-1 Overexpression in Cardiomyocytes Induces Downregulation of p21 ^{CIP1} and p27 ^{KIP1} and Refease of Active Cyclin-Dependent Kinases in the Presence of Insulin-Like Growth Factor I," Circulation Research, Vol. 85, pp. 128-136, 1992.							
16.		Carrano, et al., "SKP2 is Required for Ubiquitin-mediated Degradation of the CDK Inhibitor p27," Nature Cell Biology, Vol. 1, pg. 193-199, August 1999.						
17.	Bornstein, et al., "Role of the SCF ^{Sap2} Ubiquitin Ligase in the Degradation of p21 ^{Cp1} in S Phase," The Journal of Biological Chemistry, Vol. 278, No. 28, pg. 25752-25757, July 11, 2003.							
18.	 Kamura, et al., "Degradation of p57^{Kip2} Mediated By SCP^{Stp2}-dependent Ubiquitylation," Proc. Natl. Acad. Sci. USA, Vol. 100, No. 18, pg. 10231-10236, September 2, 2003. 							
EXAMINER SIGNATURE /Magdalene Sgagias/ DATE CONSIDERED 03/18/2010								
	R: Initial if reference considered, whether or not once and not considered. Include copy of this form			citation	if not			